KR102607967B1 - 단백질 키나제 억제제 및 추가 화학요법제의 조합물 - Google Patents

단백질 키나제 억제제 및 추가 화학요법제의 조합물 Download PDF

Info

Publication number
KR102607967B1
KR102607967B1 KR1020197020952A KR20197020952A KR102607967B1 KR 102607967 B1 KR102607967 B1 KR 102607967B1 KR 1020197020952 A KR1020197020952 A KR 1020197020952A KR 20197020952 A KR20197020952 A KR 20197020952A KR 102607967 B1 KR102607967 B1 KR 102607967B1
Authority
KR
South Korea
Prior art keywords
compound
nci
etoposide
treatment
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197020952A
Other languages
English (en)
Korean (ko)
Other versions
KR20190099253A (ko
Inventor
라르스 담스트룹
토마스 그롬바허
크리슈티안 지렌베르크
류보미르 바실레프
아스트리트 침머만
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20190099253A publication Critical patent/KR20190099253A/ko
Application granted granted Critical
Publication of KR102607967B1 publication Critical patent/KR102607967B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197020952A 2016-12-19 2017-12-18 단백질 키나제 억제제 및 추가 화학요법제의 조합물 Active KR102607967B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662436046P 2016-12-19 2016-12-19
US62/436,046 2016-12-19
PCT/EP2017/083272 WO2018114776A1 (en) 2016-12-19 2017-12-18 Combination of a protein kinase inhibitor and an additional chemotherapeutic agent

Publications (2)

Publication Number Publication Date
KR20190099253A KR20190099253A (ko) 2019-08-26
KR102607967B1 true KR102607967B1 (ko) 2023-11-29

Family

ID=60915499

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197020952A Active KR102607967B1 (ko) 2016-12-19 2017-12-18 단백질 키나제 억제제 및 추가 화학요법제의 조합물

Country Status (8)

Country Link
US (1) US11246929B2 (enExample)
EP (1) EP3554495B1 (enExample)
JP (1) JP7113826B2 (enExample)
KR (1) KR102607967B1 (enExample)
AU (1) AU2017384134B2 (enExample)
CA (1) CA3047449C (enExample)
ES (1) ES3040063T3 (enExample)
WO (1) WO2018114776A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
EP3992189A4 (en) * 2019-06-27 2022-12-07 Medshine Discovery Inc. QUINAZOLINE AND CINNOLINE DERIVATIVES AS DNA PK INHIBITORS
WO2022143671A1 (zh) * 2020-12-28 2022-07-07 南京明德新药研发有限公司 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281431A1 (en) 2012-04-24 2013-10-24 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
CN1861050A (zh) * 2006-06-21 2006-11-15 山东蓝金生物工程有限公司 一种同载铂类化合物及其增效剂的抗癌药物缓释注射剂
EP2205242B1 (en) 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
CN102014913A (zh) 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
PL3424920T3 (pl) * 2013-10-17 2020-11-16 Vertex Pharmaceuticals Incorporated Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281431A1 (en) 2012-04-24 2013-10-24 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Indian Journal of cancer, Vol. 48, No. 4, p. 454
International Journal of biochemistry and cell biology, vol. 53, pp. 423-431 (2014.08.01.)

Also Published As

Publication number Publication date
WO2018114776A1 (en) 2018-06-28
US20190365896A1 (en) 2019-12-05
CA3047449A1 (en) 2018-06-28
ES3040063T3 (en) 2025-10-28
US11246929B2 (en) 2022-02-15
JP2020502182A (ja) 2020-01-23
JP7113826B2 (ja) 2022-08-05
AU2017384134B2 (en) 2022-03-24
CA3047449C (en) 2023-07-04
AU2017384134A1 (en) 2019-08-01
EP3554495A1 (en) 2019-10-23
KR20190099253A (ko) 2019-08-26
EP3554495B1 (en) 2025-06-04

Similar Documents

Publication Publication Date Title
JP7194022B2 (ja) Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
EP3453392B1 (en) Therapeutic agent for lung cancer that has acquired egfr-tki resistance
JP2016535756A (ja) ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
US20250352598A1 (en) Improved Therapeutic Index of Anti-Immune Checkpoint Inhibitors Using Combination Therapy Comprising A PHY906 Extract, A Scutellaria baicalensis Georgi (S) Extract or A Compound From Such Extracts
EP3811946A1 (en) Use of cdk4/6 inhibitor in combination with egfr inhibitor in the preparation of medicament for treating tumor diseases
TW202302095A (zh) 使用ｂｅｔ抑制劑治療骨髓纖維化
KR102607967B1 (ko) 단백질 키나제 억제제 및 추가 화학요법제의 조합물
EP2707001B1 (en) Method for treatment of solid malignancies including advanced or metastatic solid malignancies
WO2022052874A1 (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
WO2020114348A1 (en) Methods for cancer therapy
JP7762796B2 (ja) Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
CN117257782A (zh) 美利曲辛在逆转奥希替尼耐药中的应用
CN111214475B (zh) 一种抗双重打击淋巴瘤的联合用药物组合物及其应用
US20190183893A1 (en) Low dose of sildenafil as an antitumor drug
KR20220124739A (ko) 암의 치료를 위한 병용 요법
RU2785997C1 (ru) Комбинация ингибитора протеинкиназы и дополнительного химиотерапевтического средства
WO2021018310A1 (zh) 用于治疗非小细胞肺癌的氨基吡啶衍生物
CN110638802A (zh) Atca在制备治疗肿瘤的药物中的用途
TW202434219A (zh) 使用乏氧激活化合物治療對parp抑制劑耐藥的患者的藥物及其製藥用途
US20230102831A1 (en) Composition for preventing, alleviating or treating cancer
WO2022171064A1 (zh) 烟酰胺及含有其的组合物的制药用途
Li et al. Anaplastic Carcinoma
HK40004756B (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
HK40004756A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190717

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201217

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230210

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230825

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231127

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231127

End annual number: 3

Start annual number: 1

PG1601 Publication of registration